background
previou
studi
suggest
role
play
respiratori
virus
exacerb
cystic
fibrosi
cf
howev
impact
respiratori
virus
could
underestim
low
detect
rate
convent
laboratori
method
method
children
cf
nasal
swab
sputum
sampl
obtain
routin
basi
develop
respiratori
exacerb
nucleic
acid
sequenc
base
amplif
nasba
use
detect
respiratori
virus
nasal
swab
definit
respiratori
exacerb
symptom
score
total
peak
expiratori
flow
fell
lmin
child
usual
best
valu
parent
subject
felt
child
develop
cold
result
patient
report
episod
respiratori
exacerb
exacerb
sampl
obtain
posit
respiratori
virus
contrast
asymptomat
nasal
swab
posit
respiratori
virus
significantli
virus
detect
respiratori
exacerb
particular
influenza
influenza
b
rhinoviru
p
b
upper
respiratori
symptom
significantli
correl
posit
respiratori
viral
detect
p
b
studi
also
show
viral
respiratori
exacerb
cf
could
independ
bacteri
infect
conclus
respiratori
virus
associ
exacerb
cf
upper
respiratori
symptom
strong
predictor
presenc
realtim
nasba
rapid
turnaround
time
potenti
aid
clinic
decis
make
use
antivir
administr
antibiot
life
expect
cystic
fibrosi
cf
patient
increas
dramat
last
year
howev
progress
pulmonari
damag
eventu
respiratori
failur
still
major
caus
morbid
mortal
cf
bacteri
infect
gener
thought
major
caus
clinic
deterior
recent
evid
literatur
show
respiratori
virus
lead
pulmonari
exacerb
diseas
progress
increas
bacteri
adher
cf
airway
vitro
studi
result
prolong
hospit
cf
patient
infect
virus
true
impact
cf
may
yet
underestim
previou
studi
number
reason
firstli
respiratori
virus
may
trigger
bacteri
infect
presenc
bacteria
necessarili
exclud
viral
infect
secondli
mani
previou
studi
use
tissu
cultur
immunofluoresc
techniqu
rel
insensit
method
viral
detect
techniqu
use
publish
studi
cf
thirdli
studi
use
sensit
method
molecular
base
techniqu
viral
detect
final
mani
previou
studi
poorli
design
small
studi
sampl
use
invalid
criteria
defin
pulmonari
exacerb
therefor
provid
bias
result
identifi
respiratori
virus
cf
import
clinic
decis
make
potenti
import
new
antivir
becom
readili
avail
prospect
studi
conduct
month
decemb
may
involv
patient
cf
age
year
four
cf
centr
name
univers
hospit
wale
cardiff
royal
gwent
hospit
newport
singleton
hospit
swansea
nevil
hall
hospit
abergavenney
nasal
swab
obtain
patient
whenev
develop
symptom
suggest
respiratori
exacerb
whenev
attend
routin
outpati
assess
monthli
basi
nasal
swab
obtain
insert
steril
cotton
swab
one
nostril
depth
cm
swab
subject
ml
guanidium
thiocyan
lysi
buffer
transport
ice
pack
laboratori
store
undergo
nucleic
acid
extract
later
date
pair
sputumcough
swab
sampl
also
obtain
time
bacteriolog
analys
nation
public
health
servic
nph
wale
respiratori
viru
nucleic
acid
materi
extract
nasal
swab
use
silica
slurri
describ
boom
et
al
extract
materi
amplifi
realtim
use
nucleic
acid
sequenc
base
amplif
nasba
conjunct
molecular
beacon
panel
respiratori
virus
studi
includ
influenza
influenza
b
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
type
rhinoviru
coronaviru
sequenc
primer
molecular
beacon
use
realtim
nasba
assay
shown
tabl
analysi
result
undertaken
use
easi
q
analys
ltd
isotherm
result
avail
within
min
nasba
assay
found
highli
sensit
tissu
cultur
infect
dose
viru
input
tcid
copi
synthet
rna
assay
also
specif
background
signal
detect
crossreact
panel
includ
rang
respiratori
virus
lysi
buffer
neg
control
cutoff
threshold
posit
result
defin
neg
control
wildtyp
signal
bacteri
isol
studi
perform
nph
wale
method
base
antibiot
treatment
cf
publish
cf
trust
report
wwwcftrustorguk
standard
oper
procedur
bsop
nation
standard
procedur
investig
bronchoalveolar
lavag
sputum
associ
specimen
issu
standard
unit
evalu
standard
laboratori
specialist
refer
microbiolog
divis
wwwhpaorguk
studi
patient
parent
provid
symptom
diari
card
compris
upper
lower
respiratori
symptom
includ
runni
nose
block
nose
sore
throat
hoars
voic
fevershiv
cough
daytim
nighttim
wheez
daytim
nighttim
short
breath
school
absente
patient
parent
ask
score
symptom
use
diari
card
regularli
symptom
score
symptom
mild
symptom
moder
symptom
sever
symptom
criterion
patient
age
year
also
provid
miniwright
peak
flow
meter
ask
record
best
three
read
everi
morn
even
definit
respiratori
exacerb
symptom
score
total
peak
expiratori
flow
fell
lmin
child
usual
best
valu
parent
subject
felt
child
develop
cold
circumst
parent
patient
encourag
contact
investig
nasal
swab
taken
patient
parent
remind
regularli
throughout
studi
telephon
letter
contact
investig
event
respiratori
exacerb
record
peak
expiratori
flow
symptom
score
studi
protocol
approv
committe
ethic
individu
hospit
research
fund
grant
welsh
offic
research
develop
word
inform
consent
obtain
least
one
parent
begin
studi
children
parent
inform
sheet
also
provid
clariti
statist
analysi
studi
perform
use
softwar
packag
graphpad
instat
version
window
graphpad
softwar
san
diego
ca
author
fc
chisquar
test
fisher
exact
test
use
compar
incid
respiratori
viral
infect
routin
exacerb
sampl
fisher
exact
test
also
use
compar
reason
use
defin
respiratori
exacerb
viru
posit
viru
neg
group
chisquar
test
use
studi
correl
respiratori
virus
bacteria
pvalu
taken
statist
signific
patient
cf
care
four
centr
invit
particip
studi
patient
parent
kindli
agre
enrol
male
predomin
total
boy
girl
particip
median
age
year
studi
popul
homozyg
delta
heterozygot
genet
mutat
fev
predict
greater
studi
popul
colonis
pseudomona
aeruginosa
staphylococcu
aureu
respect
tabl
demograph
particip
studi
n
similar
join
studi
report
case
respiratori
exacerb
volunt
month
studi
period
maximum
number
report
one
child
sampl
obtain
report
exacerb
case
discrep
number
aros
volunt
refus
nasal
swab
taken
home
sampl
collect
asleep
point
sampl
collect
sampl
miss
median
number
sampl
taken
patient
rang
respiratori
virus
detect
realtim
nasba
case
six
case
two
virus
detect
three
case
three
detect
tabl
influenza
influenza
b
piv
rhinoviru
major
virus
detect
routin
sampl
collect
patient
median
number
routin
sampl
collect
patient
rang
altern
routin
sampl
analys
studi
due
financi
constraint
sampl
posit
respiratori
virus
routin
collect
tabl
piv
rhinoviru
major
virus
detect
significantli
respiratori
virus
detect
exacerb
sampl
routin
sampl
pvalu
particular
significantli
patient
snot
popul
greater
year
age
abl
perform
lung
function
patient
declin
join
studi
greater
year
age
abl
perform
lung
function
test
influenza
p
influenza
b
p
rhinovirus
p
detect
exacerb
sampl
tabl
influenza
detect
eleven
exacerb
sampl
two
occas
routin
sampl
p
similarli
influenza
b
detect
eleven
exacerb
sampl
compar
none
routin
sampl
p
rhinovirus
also
commonli
found
exacerb
sampl
p
piv
isol
nasal
specimen
occas
exacerb
routin
sampl
differ
two
sampl
type
signific
p
episod
respiratori
exacerb
summat
symptom
score
use
occas
defin
respiratori
exacerb
peak
flow
fall
greater
lmin
usual
best
use
occas
subject
evalu
use
occas
defin
episod
respiratori
exacerb
exacerb
nasal
swab
sampl
divid
viru
posit
group
least
one
viru
identifi
nasal
swab
n
viru
neg
group
n
viru
identifi
nasal
swab
significantli
patient
viru
posit
group
use
summat
symptom
score
defin
exacerb
episod
exacerb
viru
posit
group
comparison
episod
viru
neg
group
p
mean
symptom
score
respiratori
exacerb
viru
posit
group
compar
viru
neg
group
though
differ
signific
differ
proport
patient
use
peak
expiratori
flow
reduct
use
subject
evalu
defin
exacerb
two
group
significantli
higher
proport
patient
viru
posit
group
complain
upper
respiratori
tract
symptom
runni
nose
versu
pvalu
sore
throat
versu
pvalu
exacerb
frequenc
lower
respiratori
tract
complaint
similar
two
group
subgroup
analysi
perform
compar
sampl
posit
either
influenza
influenza
b
group
posit
viral
infect
viru
posit
exacerb
sampl
account
respiratori
virus
detect
posit
influenza
b
sampl
exclud
analysi
also
respiratori
virus
identifi
addit
influenza
viru
one
remain
sampl
contain
influenza
b
virus
sampl
posit
respiratori
virus
reason
use
report
respiratori
exacerb
similar
influenza
viral
group
summat
symptom
score
major
reason
use
defin
respiratori
exacerb
group
influenza
group
viral
group
howev
significantli
upper
respiratori
symptom
complaint
includ
runni
nose
pvalu
block
nose
pvalu
sore
throat
pvalu
hoars
voic
pvalu
fever
shiveri
episod
pvalu
influenza
group
compar
viral
group
differ
lower
respiratori
symptom
complaint
group
pair
sputum
samplescough
swab
analys
bacteri
isol
exacerb
routin
consist
cough
swab
sputum
sampl
specimen
posit
bacteria
account
total
isol
cough
swab
specimen
posit
sputum
sampl
posit
p
aeruginosa
aureu
major
bacteria
isol
account
bacteria
identifi
respect
nasal
swab
exacerb
routin
sampl
posit
least
one
respiratori
viru
pair
sputumcough
swab
sampl
posit
bacteria
similarli
nasal
swab
sampl
virus
identifi
posit
bacteria
henc
statist
differ
viral
nonvir
group
term
bacteria
isol
p
also
differ
pseudomona
isol
viral
nonvir
group
nasal
swab
sampl
consid
term
routineasymptomat
n
exacerb
n
collect
differ
found
two
group
term
bacteri
infect
statu
p
bacteria
found
routin
sampl
exacerb
sampl
novel
studi
use
realtim
nasba
examin
role
respiratori
virus
cf
achiev
highest
detect
rate
amongst
exist
literatur
concern
respiratori
virus
cf
popul
report
episod
respiratori
ill
result
compar
favour
previou
studi
may
earlier
studi
reli
heavili
repeat
serolog
test
either
alon
combin
viral
isol
tradit
method
rel
insensit
may
underestim
preval
virus
cf
also
achiev
viral
detect
rate
routin
nasal
sampl
compar
seroconvers
rate
report
wang
et
al
valu
also
similar
seroconvers
rate
asymptomat
sampl
achiev
ramsey
et
al
amongst
stabl
asthmat
children
johnston
et
al
found
viral
detect
rate
pcr
therefor
laboratori
method
higher
sensit
viral
detect
use
studi
increas
detect
rate
asymptomat
sampl
impli
high
detect
rate
exacerb
sampl
unlik
due
fals
posit
result
piv
report
caus
sever
respiratori
infect
previous
healthi
children
lead
increas
risk
hospit
admiss
knowledg
first
studi
show
detect
cf
lack
data
regard
cf
may
activ
sought
previou
studi
may
also
due
lack
knowledg
viru
studi
show
isol
cf
could
lead
pulmonari
exacerb
studi
requir
fulli
defin
exact
role
piv
cf
exacerb
studi
demonstr
influenza
b
virus
major
virus
caus
respiratori
exacerb
cf
virus
commonli
detect
pulmonari
exacerb
virus
found
studi
influenza
virus
b
figur
consist
major
previou
studi
show
influenza
viru
repres
virus
detect
relat
influenza
vaccin
uptak
rate
season
data
studi
popul
signific
influenza
detect
rate
studi
could
easili
higher
vaccin
uptak
high
previou
studi
shown
rsv
also
import
virus
cf
exacerb
repres
virus
cf
highest
incid
young
children
studi
report
virus
rsv
low
detect
rate
may
due
nasal
swab
use
sampl
collect
lower
detect
rate
nasopharyng
aspir
rsv
rsv
rel
labil
viru
amount
viru
smallvolum
nasal
swab
specimen
may
lot
less
sampl
obtain
aspir
addit
rsv
commonli
infect
lower
airway
sampl
upper
airway
nasal
swab
could
underestim
true
preval
decemb
could
potenti
miss
month
worth
valuabl
specimen
lastli
rsv
infect
report
amongst
children
age
year
median
age
year
studi
popul
may
account
low
rsv
detect
rate
howev
follow
review
case
histori
volunt
occas
respiratori
exacerb
diminish
peak
flow
report
therefor
total
number
case
respiratori
exacerb
month
give
exacerb
rate
per
patient
per
year
compar
report
previou
studi
year
sinc
wang
et
al
describ
relationship
respiratori
viral
infect
deterior
clinic
statu
cf
virus
identifi
repeat
serolog
nasal
lavag
viral
isol
patient
cf
mean
age
year
year
although
cf
patient
respiratori
ill
sibl
control
versu
differ
viru
identif
rate
virus
identifi
seroconvers
none
detect
viral
cultur
total
acut
episod
versu
asymptomat
episod
serum
sampl
infect
identifi
infect
identifi
asymptomat
period
therefor
viral
detect
rate
acut
episod
asymptomat
episod
compar
detect
rate
respect
studi
also
show
rhinovirus
play
major
role
exacerb
cf
contrast
wang
et
al
fail
detect
rhinovirus
author
conclud
high
serotyp
rhinovirus
make
detect
serolog
cultur
imposs
ramsey
et
al
prospect
compar
incid
effect
viral
infect
pulmonari
function
clinic
score
schoolchildren
cf
age
year
unaffect
sibl
period
oropharyng
cultur
serolog
test
taken
regular
two
monthli
interv
acut
exacerb
respiratori
virus
total
acut
respiratori
ill
ari
episod
occur
patient
cf
episod
associ
viru
identifi
gave
viral
detect
rate
cf
exacerb
rate
asymptomat
unabl
demonstr
signific
advers
effect
viral
infect
lung
function
patient
cf
howev
found
patient
cf
frequent
viral
infect
infect
associ
significantli
slower
rate
clinic
declin
author
also
suggest
viral
infect
may
possibl
protect
pseudomona
acquisit
rhinoviru
found
major
viru
cf
exacerb
studi
date
studi
prospect
use
molecular
base
method
identifi
viral
agent
period
smyth
et
al
prospect
investig
patient
cf
mean
age
year
use
combin
viral
cultur
immunofluores
seroconvers
fourfold
increas
titr
pcr
base
method
rhinovirus
studi
subject
report
respiratori
exacerb
episodespatientyear
compar
studi
viral
agent
identifi
episod
rhinoviru
equal
distribut
virus
identifi
almost
alway
seroconvers
also
found
children
nonrhinoviru
identifi
significantli
greater
declin
fev
wherea
patient
rhinoviru
infect
fewer
declin
collinson
et
al
follow
children
cf
month
period
use
combin
viral
cultur
pcr
picornavirus
alon
thirti
eight
children
complet
studi
symptomat
upper
respiratori
infect
episodeschildyear
sampl
avail
episod
picornavirus
identifi
episod
rhinovirus
studi
confirm
import
viru
cf
exacerb
similar
find
exacerb
episod
significantli
patient
viru
posit
group
use
summat
symptom
score
defin
respiratori
exacerb
compar
viru
neg
group
possibl
viru
posit
group
higher
percept
awar
increas
respiratori
symptom
suggest
patient
upper
respiratori
symptom
like
viru
isol
nasal
swab
differ
symptomolog
even
strike
patient
divid
subgroup
influenza
posit
viral
posit
influenza
subgroup
significantli
upper
respiratori
tract
symptom
respiratori
exacerb
compar
viru
group
differ
term
lower
respiratori
complaint
import
observ
confirm
influenza
like
infect
upper
airway
addit
recent
shown
influenza
vaccin
offer
protect
subsequ
acquisit
patient
cf
contradictori
recent
cochran
review
recent
develop
intranas
vaccin
may
effect
attract
option
offer
local
protect
upper
airway
help
arrest
infect
earli
phase
symptom
complic
aris
data
avail
optim
method
respiratori
viral
detect
limit
best
site
collect
materi
viral
detect
may
differ
differ
virus
use
bronchoalveolar
lavag
bal
obtain
lower
airway
specimen
rsv
nasal
swab
upper
airway
sampl
rhinoviru
influenza
viru
collect
nasal
swab
simpl
conveni
rel
painless
requir
addit
devic
electr
suction
devic
obtain
nasopharyng
aspir
npa
specialis
skill
thu
far
data
compar
sensit
specif
differ
sampl
techniqu
incorpor
molecular
detect
method
viral
detect
futur
studi
may
worth
obtain
specimen
differ
respiratori
site
use
differ
sampl
method
simultan
may
increas
diagnost
yield
establish
impact
respiratori
viru
cf
bacteri
isol
rate
studi
low
posit
sampl
compar
studi
olesen
et
al
achiev
bacteri
detect
rate
may
sampl
obtain
bacteri
isol
studi
cough
swab
wherea
olesen
et
al
use
combin
laryng
aspir
sputum
sampl
isol
tend
higher
isol
rate
brompton
studi
cough
swab
specif
compar
sputum
sampl
bacteria
isol
sensit
anoth
studi
conduct
maiya
et
al
show
similar
sensit
cough
swab
compar
sputum
sampl
cough
plate
bronchoalveolar
lavag
laryng
aspir
may
superior
procedur
carri
higher
risk
cost
requir
expertis
consider
must
taken
account
utilis
procedur
routin
screen
research
purpos
studi
chang
incid
bacteri
infect
viral
infect
symptomat
viral
infect
increas
likelihood
bacteri
infect
therefor
criteria
use
studi
defin
respiratori
exacerb
poor
predictor
bacteri
infect
introduct
addit
antibiot
situat
may
difficult
decid
addit
ramsey
et
al
shown
cf
patient
colonis
aureu
increas
risk
viral
infect
colonis
p
aeruginosa
protect
viral
infect
henc
high
proport
aureu
p
aeruginosa
found
studi
may
part
explain
lack
associ
virus
bacteria
nasba
use
studi
viral
identif
offer
sever
advantag
firstli
develop
specif
rna
target
amplif
particularli
suit
detect
rna
virus
need
separ
revers
transcript
step
unlik
pcr
secondli
select
criteria
nasba
primer
less
stringent
allow
easier
primer
design
select
lessconserv
region
gene
thirdli
continu
isotherm
process
requir
thermocycl
henc
constant
temperatur
throughout
amplif
reaction
allow
nasba
amplifi
target
rna
dna
exponenti
step
reaction
nasba
reaction
also
effici
pcr
method
restrict
binari
increas
per
cycl
fourthli
background
dna
interfer
nasba
reaction
singlestrand
rna
sequenc
specif
target
unlik
pcr
background
dna
may
caus
fals
posit
result
closedtub
format
nasba
assay
greatli
reduc
risk
contamin
thu
fals
posit
result
final
detect
pcr
product
requir
gel
electrophoresi
necessit
transfer
resolv
nucleic
acid
agaros
gel
labour
intens
timeconsum
well
suit
diagnost
use
compar
realtim
nasba
studi
differ
hospitalis
rate
viral
nonvir
group
patient
could
admit
hospit
nonrespiratori
reason
deem
robust
endpoint
similarli
studi
use
intraven
antibiot
viral
nonvir
group
one
endpoint
studi
felt
antibiot
sometim
administ
reason
pulmonari
exacerb
holiday
school
examin
order
improv
lung
function
respiratori
reserv
assay
identifi
human
metapneumoviru
hmpv
viru
recent
report
close
relat
taxonom
rsv
viru
possibl
account
unexplain
respiratori
infect
children
winter
season
garcia
et
al
recent
shown
viru
behav
similarli
rsv
cf
lead
increas
risk
hospitalis
exacerb
result
provid
evid
support
respiratori
virus
commonli
found
respiratori
exacerb
cf
particularli
influenza
influenza
b
rhinoviru
piv
detect
first
time
cf
popul
exact
role
need
defin
howev
littl
evid
suggest
viral
infect
predispos
bacteri
infect
contrari
previou
report
role
respiratori
virus
cf
becom
promin
entiti
realtim
nasba
viral
detect
may
play
pivot
role
futur
manag
cf
rapid
turnaround
result
may
provid
guidanc
clinician
regard
antivir
administr
thu
avoid
inappropri
use
antibiot
support
import
patient
segreg
moment
nasba
larg
remain
research
tool
clinician
use
matter
judgement
clinic
accruement
diagnos
viral
infect
mani
current
avail
diagnost
tool
still
take
day
week
provid
definit
result
hope
one
day
nasba
may
becom
wide
avail
allow
respiratori
viral
test
becom
part
routin
investig
pulmonari
exacerb
cf
addit
nasba
may
also
becom
import
screen
tool
exacerb
respiratori
ill
chronic
obstruct
pulmonari
diseas
asthma
bronchiectasi
